+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Increase by 10% of spine bone mineral density and effect on bone markers of three monthly intravenous injections of ibandronate in osteoporosis in men with Klinefelters syndrome



Increase by 10% of spine bone mineral density and effect on bone markers of three monthly intravenous injections of ibandronate in osteoporosis in men with Klinefelters syndrome



Journal of Bone & Mineral Research 15(Suppl 1): S226




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035115727

Download citation: RISBibTeXText


Related references

The effect of monthly ibandronate on bone mineral density and bone turnover markers in patients with haemophilia A and B and increased risk for fracture. Thrombosis and Haemostasis 110(2): 257-263, 2013

The effects of ibandronate on bone mineral density and bone remodelling in Klinefelters syndrome. Journal of Bone & Mineral Research 14(Suppl. 1): S405, 1999

Increased bone mineral density with monthly intravenous ibandronate contributes to fracture risk reduction in patients with primary osteoporosis: three-year analysis of the MOVER study. Calcified Tissue International 95(6): 557-563, 2014

Effects of 3 years of intravenous pamidronate treatment on bone markers and bone mineral density in a patient with osteoporosis-pseudoglioma syndrome (OPPG). Journal of Pediatric Endocrinology & Metabolism 19(3): 275-279, 2006

Higher response with bone mineral density increase with monthly injectable ibandronate 1 mg compared with oral risedronate in the MOVER study. Journal of Bone and Mineral Metabolism 34(6): 678-684, 2016

The effects of three-month intravenous ibandronate on bone mineral density and bone remodeling in Klinefelter's syndrome: the influence of vitamin D deficiency and hormonal status. Bone 33(4): 589-596, 2003

Serum sclerostin levels associated with lumbar spine bone mineral density and bone turnover markers in patients with postmenopausal osteoporosis. Chinese Medical Journal 126(13): 2480-2484, 2013

Serum Sema4D levels are associated with lumbar spine bone mineral density and bone turnover markers in patients with postmenopausal osteoporosis. International Journal of Clinical and Experimental Medicine 8(9): 16352-7, 2015

Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study. Clinical Rheumatology 24(3): 232-238, 2005

Similar improvements in hip bone mineral density with monthly oral ibandronate (150mg) versus weekly oral alendronate (70mg) in postmenopausal osteoporosis. 2007

Intermittent intravenous ibandronate injections are more effective than daily oral ibandronate for improving bone density at the hip: DIVA 2-year analysis. 2006

Three-monthly 2mg intravenous ibandronate injections restore bone turnover to premenopausal levels. Journal of Bone & Mineral Research 17(Suppl 1): S472, 2002

Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study. Osteoporosis International 25(7): 1945-1951, 2014

Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in with osteoporosis. Zhonghua Yixue Yichuanxue Zazhi 23(2): 129-133, 2006

Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 23(2): 129-133, 2006